1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
1.8. Key Benefits to the Stakeholder
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Research Processes
3. EXECUTIVE SUMMARY
3.1. Key Findings
3.2. CXO Perspective
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
4.5. Analyst View
5. IGA NEPHROPATHY DISEASE TREATMENT MARKET BY TEST
5.1. Introduction
5.2. Blood Test
5.3. Urine Test
5.4. Kidney Test
5.5. Iothalamate Clearance Test
5.6. Others
6. IGA NEPHROPATHY DISEASE TREATMENT MARKET BY TREATMENT TYPE
6.1. Introduction
6.2. Corticosteroids
6.3. Immunosuppressive Drugs
6.4. Ace Inhibitors and Arbs
6.5. Diet Change
6.6. Therapy
7. IGA NEPHROPATHY DISEASE TREATMENT MARKET BY GEOGRAPHY
7.1. Introduction
7.2. North America
7.2.1. USA
7.2.2. Canada
7.2.3. Mexico
7.3. South America
7.3.1. Brazil
7.3.2. Argentina
7.3.3. Others
7.4. Europe
7.4.1. United Kingdom
7.4.2. Germany
7.4.3. France
7.4.4. Others
7.5. Middle East and Africa
7.5.1. Saudi Arabia
7.5.2. Israel
7.5.3. Others
7.6. Asia Pacific
7.6.1. China
7.6.2. Japan
7.6.3. India
7.6.4. South Korea
7.6.5. Others
8. COMPETITIVE ENVIRONMENT AND ANALYSIS
8.1. Major Players and Strategy Analysis
8.2. Market Share Analysis
8.3. Mergers, Acquisitions, Agreements, and Collaborations
8.4. Competitive Dashboard
9. COMPANY PROFILES
9.1. TRAVERE THERAPEUTICS INC.
9.2. CALLIDITAS THERAPEUTICS AB
9.3. Omeros
9.4. NOVARTIS PHARMACEUTICALS
9.5. CHINOOK THERAPEUTICS INC
9.6. VERA THERAPEUTICS, INC
9.7. Merck KGAA
9.8. REATA PHARMACEUTICALS INC.
9.9. IONIS PHARMACEUTICALS
9.10. Stada Group